LMAT - Company ID 0001158895
LEMAITRE VASCULAR INC trades as LMAT and has a market capitalization of $2.35 B, making it the #2018 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $249.60M, up 13.5% from the prior year and net income of $57.70M. This page tracks LEMAITRE VASCULAR INC through 1,849 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-12
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years LEMAITRE VASCULAR INC's revenue grew from $89.15M to $249.60M, a compound annual growth rate of 12.1%. Net profit margin expanded from 11.9% to 23.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-07 |
| Insider sale notice | 144 | 2026-05-07 |
Artegraft grew 36% worldwide in Q1, bolstered by its international launch. Grafts (+20%), valvulotomes (+15%), and carotid shunts (+11%) each posted record sales. The three geographies also posted records: EMEA (+20%), APAC (+18%), and the Americas (+7%).
Access to the live call is available by registering online here . All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor .
Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included.
The largest companies sharing LEMAITRE VASCULAR INC's SEC industry classification (surgical & medical instruments & apparatus).
LEMAITRE VASCULAR INC (LMAT) has a market capitalization of $2.35 B as of 2026-07-12, ranking #2018 among US-listed companies.
LEMAITRE VASCULAR INC reported revenue of $249.60M for fiscal year 2025, an increase of 13.5% year over year.
Yes. LEMAITRE VASCULAR INC reported net income of $57.70M in its latest fiscal year.